The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
On Thursday, Jan. 30, the "Walking in Memphis" hitmaker posted about his Parkinson's disease diagnosis on Instagram and explained why he is sharing the news years later. "I feel like it's time to ...
A word. A sentence. A fate. Mine? Parkinson’s, the P word. It arises unbidden as I walk, my left leg not quite keeping pace with my right. It floats to top of mind when my tremor flares in a ...
Abstract: Parkinson’s Disease (PD) is a chronic and progressive neurological disorder that impairs the body’s nervous system pathways. This disruption results in multiple complications related to ...
the test is able to identify early signs of Parkinson’s disease in individuals who have not yet shown clinical symptoms, potentially offering a new pathway for earlier intervention and improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results